ASH 2017 | Study of the oral FLT3/AXL inhibitor gilteritinib for AML to move forwards
Keith Pratz
• 9 Dec 2017
There have been great advances in the targeting of FLT3 for acute myeloid leukemia (AML) in recent years, many of which were discussed at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Here, Keith Pratz, MD, of Johns Hopkins University, Baltimore, MD, discusses the promising results of a Phase I study of the oral FLT3/AXL inhibitor gilteritinib (ASP2215) in combination with standard induction and consolidation chemotherapy in patients with newly diagnosed AML, which he presented at the meeting. Dr Pratz covers response and remission rates, tolerability, and the next steps for the study.
